Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 3/20 | 0.40 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | CBX4 | O00257 | 2/20 | 0.38 |
| ▸ | CBX7 | O95931 | 2/20 | 0.38 |
| ▸ | CDYL2 | Q8N8U2 | 2/20 | 0.38 |
| ▸ | CBX8 | Q9HC52 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29129094 | 0.93 | KMT2A (0.43) | KMT2ATLR2TLR1 | |
| SCHEMBL29613490 | 0.85 | ROCK2 (0.44) | TLR2CA2CBX4CBX7CDYL2 | |
| SCHEMBL29613487 | 0.83 | CDYL2 (0.48) | KMT2ACA2PTPN1CBX4CBX7 | |
| SCHEMBL23475279 | 0.82 | PTPN1 (0.48) | KMT2ATLR2TLR1PTPN1 | |
| SCHEMBL29613485 | 0.81 | KMT2A (0.44) | KMT2ATLR2TLR1CA1CA2 | |
| SCHEMBL29613452 | 0.81 | CDYL2 (0.60) | PTPN1CBX4CBX7CDYL2CBX8 | |
| SCHEMBL29613425 | 0.81 | KLK7 (0.52) | KMT2ATLR2TLR1 | |
| SCHEMBL23463187 | 0.81 | PTPN1 (0.47) | KMT2ATLR2TLR1PTPN1 | |
| SCHEMBL23446659 | 0.80 | PTPN1 (0.47) | KMT2ATLR2PTGER4PTPN1 | |
| SCHEMBL23446150 | 0.78 | TLR2 (0.44) | KMT2ATLR2TLR1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166693-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | Design Therapeutics, Inc. | 2024-05-23 | — | — | US | disclosed |
| EP-4259133-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| WO-2022126000-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166693-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | MTPN, DMPK, MBNL1 | KMT2A 2132/4885TLR2 4702/4885TLR1 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.